S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:SOPH

SOPHiA GENETICS (SOPH) Stock Price, News & Analysis

$4.93
-0.33 (-6.27%)
(As of 03/28/2024 ET)
Today's Range
$4.93
$5.21
50-Day Range
$4.21
$5.62
52-Week Range
$2.13
$7.37
Volume
21,152 shs
Average Volume
51,896 shs
Market Capitalization
$321.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

SOPHiA GENETICS MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
62.3% Upside
$8.00 Price Target
Short Interest
Healthy
0.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of SOPHiA GENETICS in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.06) to ($0.91) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.46 out of 5 stars

Medical Sector

468th out of 938 stocks

Biological Products, Except Diagnostic Industry

75th out of 148 stocks

SOPH stock logo

About SOPHiA GENETICS Stock (NASDAQ:SOPH)

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

SOPH Stock Price History

SOPH Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Q4 2023 Sophia Genetics SA Earnings Call
Preview: Sophia Genetics's Earnings
See More Headlines
Receive SOPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SOPH
Fax
N/A
Employees
430
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+62.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-78,980,000.00
Net Margins
-126.63%
Pretax Margin
-125.85%

Debt

Sales & Book Value

Annual Sales
$62.37 million
Book Value
$3.16 per share

Miscellaneous

Free Float
62,048,000
Market Cap
$321.58 million
Optionable
Not Optionable
Beta
1.18
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Jurgi Camblong M.B.A. (Age 45)
    Ph.D., Co-Founder, CEO & Director
    Comp: $1.1M
  • Mr. Ross Jordan Muken B.Sc. (Age 43)
    Executive VP, CFO & COO
  • Mr. Abhimanyu Verma
    Senior VP & CTO
  • Dr. Zhenyu Xu Ph.D. (Age 41)
    Executive VP & Chief Scientific Officer
  • Katherine Bailon
    Vice President of Investor Relations
  • Mr. Daan van Well L.L.M. (Age 49)
    M.B.A., Executive VP, Chief Legal & Compliance Officer
  • Ms. Manuela Da Silva Valente B.A. (Age 53)
    Senior VP & Chief People Officer
  • Mr. Kevin Puylaert
    VP & MD of EMEA
  • Dr. Philippe Menu M.B.A. (Age 42)
    M.D., Ph.D., Executive VP, Chief Medical Officer & Chief Product Officer
  • Mr. Peter Casasanto
    Senior VP & Chief BioPharma Officer

SOPH Stock Analysis - Frequently Asked Questions

Should I buy or sell SOPHiA GENETICS stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SOPHiA GENETICS in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SOPH shares.
View SOPH analyst ratings
or view top-rated stocks.

What is SOPHiA GENETICS's stock price target for 2024?

2 brokers have issued 1-year target prices for SOPHiA GENETICS's shares. Their SOPH share price targets range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 62.3% from the stock's current price.
View analysts price targets for SOPH
or view top-rated stocks among Wall Street analysts.

How have SOPH shares performed in 2024?

SOPHiA GENETICS's stock was trading at $4.71 on January 1st, 2024. Since then, SOPH shares have increased by 4.7% and is now trading at $4.93.
View the best growth stocks for 2024 here
.

Are investors shorting SOPHiA GENETICS?

SOPHiA GENETICS saw a drop in short interest in March. As of March 15th, there was short interest totaling 43,000 shares, a drop of 28.6% from the February 29th total of 60,200 shares. Based on an average daily trading volume, of 48,100 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.1% of the company's stock are short sold.
View SOPHiA GENETICS's Short Interest
.

When is SOPHiA GENETICS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SOPH earnings forecast
.

How were SOPHiA GENETICS's earnings last quarter?

SOPHiA GENETICS SA (NASDAQ:SOPH) issued its earnings results on Tuesday, March, 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.12. The firm earned $17.05 million during the quarter, compared to the consensus estimate of $16.78 million. SOPHiA GENETICS had a negative trailing twelve-month return on equity of 47.40% and a negative net margin of 126.63%. During the same quarter in the prior year, the firm earned ($0.22) EPS.

What guidance has SOPHiA GENETICS issued on next quarter's earnings?

SOPHiA GENETICS updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $78.0 million-$81.0 million, compared to the consensus revenue estimate of $82.1 million.

When did SOPHiA GENETICS IPO?

SOPHiA GENETICS (SOPH) raised $234 million in an IPO on Friday, July 23rd 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share.

Who are SOPHiA GENETICS's major shareholders?

SOPHiA GENETICS's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Principal Financial Group Inc. (0.00%), Parkman Healthcare Partners LLC (0.32%), Essex Investment Management Co. LLC (0.00%), Federated Hermes Inc. (0.00%), Legato Capital Management LLC (0.00%) and Zurcher Kantonalbank Zurich Cantonalbank (0.00%).

How do I buy shares of SOPHiA GENETICS?

Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SOPH) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners